Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SynAct Pharma AB ( (SE:SYNACT) ) just unveiled an update.
SynAct Pharma AB has increased its number of shares and votes by 2,451,600 following a directed share issue and conversion of warrants in July 2025. This move, which resulted in a total of 52,326,143 shares and votes, provided the company with SEK 17.7 million, potentially strengthening its financial position and supporting its strategic initiatives in the biotechnology sector.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical stage biotechnology company listed on Nasdaq Stockholm, specializing in the resolution of inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists designed to promote anti-inflammatory activity and help patients achieve immune balance.
Average Trading Volume: 224,605
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.09B
Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.